Cinvanti

Active Ingredient(s): Aprepitant
FDA Approved: * November 9, 2017
Pharm Company: * HERON THERAPS INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Cinvanti Overview

Aprepitant, sold under the brand name Emend among others, is a medication used to prevent chemotherapy-induced nausea and vomiting (CINV) and to prevent postoperative nausea and vomiting.[1] It may be used together with ondansetron and dexamethasone.[1] It is taken by mouth.[1] Common side effects include tiredness, loss of appetite, diarrhea, abdominal pain, hiccups, itchiness, pneumonia, and blood pressure changes.[1] Other sev...

Read more Cinvanti Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Aprepitant

Recent Cinvanti Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Aprepitant
  • Capsule: 125mg, 40mg, 80mg, 80mg + 125mg
  • Emulsion: 130mg/18ml (7.2mg/ml)
  • For Suspension: 125mg/kit
  • Injection: 130mg, 150mg/vial
  • Powder: 115mg/vial, 150mg/vial
  • Solution: 125mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Cinvanti: (1 result)

Sorted by National Drug Code
  • 47426-201 Cinvanti 130 mg/18ml Intravenous Injection, Emulsion by Heron Therapeutics

Other drugs which contain Aprepitant or a similar ingredient: (4 results)